What was Granules India's revenue in Q4 FY26?

Granules India reported revenue of ₹1,476 Cr in Q4 FY26, a +23% change year-over-year.

Did Granules India management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

Granules India Q4 FY26 Research Workspace: Revenue ₹1,476 Cr (+23%)

Q: What guidance did Granules India management give?

Capex of ~₹600 crore for FY27: Capital expenditure expected around ₹600 crore, including ₹200 crore for a new distribution center in the US and investments in API facility and IT.

Revenue ₹1,476 Cr +23%

EBITDA ₹352 Cr +40%

PAT ₹202 Cr +33%

EBITDA Margin 23.9% +100bps

Duration 58 min

Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Granules India delivered a strong Q4 FY26 with revenue of ₹1,476 crore (+23% YoY), EBITDA of ₹352 crore (+40% YoY), and PAT of ₹202 crore (+33% YoY). Gross margin expanded 233bps YoY to 65.7%, driven by a favorable mix shift toward complex generics and the peptide CDMO business, which turned EBITDA-positive for the first time. Full-year revenue crossed ₹5,000 crore for the first time, growing 20% YoY. Europe revenue surged 81% YoY, now 15% of total. The Gagilapur remediation is substantially complete, with the company awaiting FDA reinspection. Guidance for FY27 includes sustained USFDA readiness, scaling of peptide CDMO, and capex of ~₹600 crore. Key risk: prolonged uncertainty in raw material and freight costs due to geopolitical tensions, which could pressure margins if price increases lag.

Risks4 trackedTranscriptfull text

Research workspace

Focused Modules

!Risks 4 risks

Risk Intelligence

Raw material and freight cost escalation

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

US Generic Ranking (IQVIA) 27th

+47 positions vs FY21

Moved from 74th in FY21 to 27th in FY26 in US generic sales value.

Controlled Substance Ranking 4th

N/A

Granules is now the 4th largest player in the US controlled substance generics space.

Peptide CDMO Revenue (FY26) ₹1,593M

N/A

Peptide CDMO contributed 3% of total revenue and turned EBITDA-positive in Q4.

Europe Revenue Growth 15% of total revenue

+81% YoY

Europe grew 81% YoY (49% ex-SEN), now representing ~15% of total revenue.

Fast read

Guidance and risk preview

Top guidance Capex of ~₹600 crore for FY27

Capital expenditure expected around ₹600 crore, including ₹200 crore for a new distribution center in the US and investments in API facility and IT.

Top risk Raw material and freight cost escalation

Geopolitical tensions in West Asia have increased raw material, packaging, and freight costs; management noted uncertainty in passing these on to c...